CTNNB1 and adrenal cortex carcinoma: CTNNB1 mutations have been observed in approximately 10–15% of ACCs17–20, although aberrant activation of Wnt/β-Catenin signaling is observed in a much higher proportion of ACC tumours, most of them are not caused by known CTNNB1 mutations11,21.